Praxis Precision Medicines (PRAX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$3.23

Estimate

-$3.63

Surprise

+11.1%

Score today

5.8/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Praxis Precision Medicines (PRAX) reported a narrower loss than forecast — adjusted EPS of -$3.23 against the -$3.63 estimate (a 11.1% beat on a still-unprofitable quarter).

• RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $478 — benzinga, 2026-11-10
• Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $189 — benzinga, 2026-11-10
• Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Lowers Price Target to $343 — benzinga, 2026-11-10

TrendMatrix currently rates PRAX Sell at 5.8/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +11.1% surprise compares with a +8.6% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$328.19

Price target

$585.00

Stop

$305.22

Upside to target

+78.2%

Reward-to-risk

5.2:1

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$9.30B

P/E (fwd)

-34.7

52-week range

$160.11–$392.70

Off 52-week high

16.4%

RSI (14)

71

Volume vs avg

0.26×

Score today

5.8/10